Patterns of Care in Patients with Metastatic Renal Cell Carcinoma Among a U.S. Payer Population with Commercial or Medicare Advantage Membership

BACKGROUND: Several systemic therapies are now approved for first- and second-line treatment of metastatic renal cell carcinoma (mRCC). Although the National Comprehensive Cancer Network (NCCN) guidelines offer physicians evidence-based recommendations for therapy, there are few real-world studies t...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Lesley-Ann, Stemkowski, Stephen, Saverno, Kim, Lane, Daniel C., Tao, Zhuliang, Hackshaw, Michelle D., Loy, Bryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397977/
https://www.ncbi.nlm.nih.gov/pubmed/27003551
http://dx.doi.org/10.18553/jmcp.2016.22.3.219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397977/
https://www.ncbi.nlm.nih.gov/pubmed/27003551
http://dx.doi.org/10.18553/jmcp.2016.22.3.219

Ejemplares similares